Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

14.16 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eton Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
Eton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sales and launch in the U.S. in June 2025. 
Via Benzinga
A Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 Analysts
 
Via Benzinga
A Look Ahead: Eton Pharmaceuticals's Earnings Forecast
 
Via Benzinga
Evaluating ETON PHARMACEUTICALS INC (NASDAQ:ETON) using Mark Minervini’s winning stock formula
A fundamental and technical analysis of (NASDAQ:ETON): Is ETON PHARMACEUTICALS INC (NASDAQ:ETON) suited for high growth investing? 
Via Chartmill
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know
 
Via Benzinga
Earnings Scheduled For March 18, 2025
 
Via Benzinga
The Analyst Verdict: Eton Pharmaceuticals In The Eyes Of 5 Experts
 
Via Benzinga
Earnings Scheduled For May 13, 2025
 
Via Benzinga
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch
Eton Pharmaceuticals' ET-600 met bioequivalence standards in a study, with an FDA filing planned for April 2025 and a potential launch in early 2026. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Analyst Expectations For Eton Pharmaceuticals's Future
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
Earnings Outlook For Eton Pharmaceuticals
 
Via Benzinga
Critical Insights From Eton Pharmaceuticals Analyst Ratings: What You Need To Know
 
Via Benzinga
Recap: Eton Pharmaceuticals Q4 Earnings
 
Via Benzinga
Eton Pharmaceuticals Earnings Preview
 
Via Benzinga
3 Stocks Insiders Are Buying Heavily In October 2024, And Why
Should investors add these stocks on their watchlist? Insider buys suggest so. 
Via Talk Markets
Domino's Pizza To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
ETON stock results show that Eton Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
ETON Stock Earnings: Eton Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
ETON stock results show that Eton Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Is NASDAQ:ETON suited for growth investing?
ETON PHARMACEUTICALS INC (NASDAQ:ETON) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
Why the growth investor may take a look at NASDAQ:ETON.
Exploring ETON PHARMACEUTICALS INC (NASDAQ:ETON)'s growth characteristics. 
Via Chartmill
Evaluating NASDAQ:ETON for Growth Investment Opportunities.
Exploring ETON PHARMACEUTICALS INC (NASDAQ:ETON)'s growth characteristics. 
Via Chartmill
ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
ETON stock results show that Eton Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
Eton Pharmaceuticals: Q3 Earnings Insights
 
Via Benzinga
Gilead Sciences Tops Q3 Earnings And Revenue Estimates
While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? 
Via Talk Markets
Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy. 
Via Benzinga
Topics Bankruptcy
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.